The COMBO dual therapy stent in patients presenting with acute ST-elevation myocardial infarction: a one-year follow-up study

Rajiv Ananthakrishna, William Kristanto, et al

Aims: The aim of this study was to evaluate the safety and efficacy of the COMBO dual therapy stent in patients with acute ST-elevation myocardial infarction (STEMI). We report the one-year clinical outcomes.

Methods and results:
Patients with acute STEMI who underwent primary percutaneous coronary intervention (PCI) between November 2013 and March 2015 and received the COMBO dual therapy stent were enrolled in this prospective single-centre registry. The primary outcome was target lesion failure (TLF), defined as a combination of cardiac mortality, target vessel myocardial infarction (TVMI), or clinically driven target lesion revascularisation (TLR). A total of 117 patients received 147 COMBO dual therapy stents during the study period, and 9.4% of the patients presented with cardiogenic shock. Thrombolysis In Myocardial Infarction (TIMI) 3 flow post procedure was achieved in 98.5% of lesions. At one year, the TLF rate was 7.7%. The rates of cardiac mortality, TVMI, and TLR were 4.3%, 2.6%, and 3.4%, respectively. The incidence of definite/probable stent thrombosis was 4.3% at 12 months, with four of the five cases occurring within 30 days. The all-cause mortality was 5.1% at one year.

COMBO stent implantation during primary PCI for acute STEMI showed acceptable rates of TLF at one year, although the rates of early ST were not negligible. Further studies are warranted to evaluate the safety in a larger high-risk population.

To download, please click below.